Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$110.02 -0.9%	$105.14	$76.53 ▼ $131.49	$26.45B	1.29	942,214 shs	616,421 shs
BPMC Blueprint Medicines	$129.46	$120.01	$73.04 ▼ $129.65	$8.36B	0.89	1.54 million shs	N/A
INSM Insmed	$102.56 -1.5%	$86.93	$60.40 ▼ $106.83	$19.46B	0.9	2.29 million shs	1.43 million shs
ONC BeOne Medicines	$294.55 +1.4%	$250.96	$152.81 ▼ $300.00	$32.28B	0.28	388,965 shs	893,521 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-2.54%	+3.28%	+8.06%	+28.74%
BPMC Blueprint Medicines	0.00%	+0.12%	+0.98%	+53.79%	+12.60%
INSM Insmed	0.00%	+4.46%	-0.12%	+47.55%	+35.00%
ONC BeOne Medicines	0.00%	+17.68%	+19.21%	+28.50%	+29,454,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	1.419 of 5 stars	3.4	2.0	0.0	1.1	0.8	0.0
BPMC Blueprint Medicines	0.9602 of 5 stars	2.1	2.0	0.0	1.5	0.8	0.6
INSM Insmed	3.9484 of 5 stars	2.5	4.0	4.3	2.8	1.7	0.6
ONC BeOne Medicines	2.6199 of 5 stars	3.5	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$136.58	24.14% Upside
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.93% Downside
INSM Insmed	3.00	Buy	$108.47	5.76% Upside
ONC BeOne Medicines	3.00	Buy	$327.56	11.21% Upside

Current Analyst Ratings Breakdown

Latest BPMC, ONC, BNTX, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $126.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.88	N/A	N/A	$87.61 per share	1.26
BPMC Blueprint Medicines	$562.12M	14.87	N/A	N/A	$4.70 per share	27.54
INSM Insmed	$363.71M	53.49	N/A	N/A	$1.60 per share	64.10
ONC BeOne Medicines	$3.81B	8.47	N/A	N/A	$34.10 per share	8.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.17	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	414.86	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)

Latest BPMC, ONC, BNTX, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.38	N/A	N/A	N/A	$161.26 million	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
BPMC Blueprint Medicines	1.01	2.80	2.75
INSM Insmed	11.38	5.86	5.44
ONC BeOne Medicines	0.05	1.96	1.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
BPMC Blueprint Medicines	N/A
INSM Insmed	N/A
ONC BeOne Medicines	48.55%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
BPMC Blueprint Medicines	4.21%
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A

BPMC, ONC, BNTX, and INSM Headlines

Recent News About These Companies

BeOne Medicines (NASDAQ:ONC) Sets New 52-Week High After Analyst Upgrade

July 19 at 2:23 AM | americanbankingnews.com

The S&P 500 and Nasdaq Are Joined By These Stocks Hitting New Highs

July 18 at 5:11 PM | msn.com

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

July 18 at 1:41 PM | marketbeat.com

BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?

July 18 at 11:11 AM | zacks.com

BeOne Medicines (NASDAQ:ONC) Price Target Raised to $349.00

July 18 at 3:21 AM | americanbankingnews.com

BeOne Medicines (NASDAQ:ONC) Hits New 52-Week High on Analyst Upgrade

July 17, 2025 | marketbeat.com

Looming Tariffs Don't Scare This Swiss Cancer Treatment Stock

July 16, 2025 | msn.com

Royal Bank Of Canada Increases BeOne Medicines (NASDAQ:ONC) Price Target to $349.00

July 16, 2025 | marketbeat.com

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

July 16, 2025 | businesswire.com

EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

July 16, 2025 | pmlive.comP

BeOne Medicines (NASDAQ:ONC) Shares Gap Up - Here's Why

July 15, 2025 | marketbeat.com

BeOne Medicines (NASDAQ:ONC) Rating Lowered to Hold at Wall Street Zen

July 14, 2025 | americanbankingnews.com

Biocytogen Enters into Antibody Licensing Agreement with BeOne ...

July 13, 2025 | businesswire.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO John Oyler Sells 27,802 Shares

July 12, 2025 | insidertrades.com

BeOne Medicines (NASDAQ:ONC) Cut to Hold at Wall Street Zen

July 12, 2025 | marketbeat.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock

July 11, 2025 | marketbeat.com

BeOne Medicines Ltd. American Depositary Shares (ONC) Insider Activity

July 11, 2025 | nasdaq.com

Brokerages Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $320.67

July 11, 2025 | americanbankingnews.com

Biocytogen inks antibody deal with BeOne, expanding strategic ties

July 10, 2025 | thepharmaletter.comT

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

July 10, 2025 | ncnewsonline.comN

NICE moves fast on Brukinsa in MCL

July 10, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
These 3 Dividend Stocks Are Not Concerned With Tariff Noise
By Thomas Hughes | July 11, 2025
View These 3 Dividend Stocks Are Not Concerned With Tariff Noise
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders
MarketBeat Week in Review – 07/07 - 07/11
By MarketBeat Staff | July 12, 2025
View MarketBeat Week in Review – 07/07 - 07/11

BPMC, ONC, BNTX, and INSM Company Descriptions

BioNTech NASDAQ:BNTX

$110.02 -1.02 (-0.92%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$110.32 +0.30 (+0.27%)

As of 05:31 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Blueprint Medicines NASDAQ:BPMC

$129.46 0.00 (0.00%)

As of 07/18/2025

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Insmed NASDAQ:INSM

$102.56 -1.61 (-1.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$102.74 +0.17 (+0.17%)

As of 04:48 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$294.55 +4.20 (+1.45%)

As of 07/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time